Crossmark

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer

Crossref DOI link: https://doi.org/10.1186/s13058-022-01547-7

Published Online: 2022-07-18

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Salvati, Annamaria

Melone, Viola

Sellitto, Assunta

Rizzo, Francesca

Tarallo, Roberta

Nyman, Tuula A.

Giurato, Giorgio

Nassa, Giovanni

Weisz, Alessandro
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro ((IG-23068))

Regione Campania ((GENOMAeSALUTE, CUP B41C17000080007))
License Information

Text and Data Mining valid from 2022-07-18

Version of Record valid from 2022-07-18
More Information

Article History

Received: 15 December 2021

Accepted: 3 July 2022

First Online: 18 July 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below